Considerations for understanding systematic reviews and network meta-analyses in neurological applications: a review and critique in chronic migraine
Publication: Journal of Comparative Effectiveness Research
Abstract
Network meta-analysis (NMA) is an evidence synthesis approach that combines direct and indirect evidence to estimate the relative effects of multiple treatments, including comparisons for which head-to-head clinical trial evidence is unavailable. Although methodological and reporting guidelines for NMAs and their accompanying systematic reviews are well established, we posit that such guidelines are not always followed in practice. In this narrative perspective, we provide a concise overview of key guidelines for conducting and reporting systematic reviews and NMAs and critically appraise two recent NMAs in chronic migraine that deviate from these recommendations. While a broader systematic review was not undertaken and the identified shortcomings of these two NMAs may not be representative of the wider NMA landscape in the neurology literature, we nevertheless encourage readers of published systematic reviews and NMAs to carefully evaluate the underlying data and methods used in evidence synthesis and to interpret findings with appropriate caution, favoring analyses conducted in accordance with rigorous best practice standards.
Supplementary Material
File (supplementary materials.docx)
References
Papers of special note have been highlighted as: • of interest
1.
Dias S, Ades A, Welton N, Jansen J, Sutton A. Network Meta-Analysis For Decision Making. John Wiley & Sons Ltd, NJ, USA (2018).
• A detailed textbook on conducting network meta-analysis (NMA), from theoretical assumptions to practical techniques.
2.
van Valkenhoef G, Kuiper J. Gemtc: network meta-analysis using Bayesian methods. (2026). https://CRAN.R-project.org/package=gemtc
3.
Seo M, Schmid C. Bnma: bayesian network meta-analysis using ‘jags’. (2025). https://cran.r-project.org/package=bnma
4.
Rücker G, Krahn U, König J et al. Netmeta: network meta-analysis using frequentist methods. (2026). https://cran.r-project.org/package=netmeta
5.
Phillippo D, Perren S, Dunnewind N. Multinma: bayesian network meta-analysis of individual and aggregate data. (2026). https://cran.r-project.org/package=multinma
6.
Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777–784 (2015).
• Outlines what authors of systematic reviews and network meta-analyses should present in their publications in order for the review to be transparent in reporting.
7.
Ornello R, Caponnetto V, Ahmed F et al. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia 45(4), 3331024251321500 (2025).
8.
Zhao C, Li C, Yu X, Dai X, Zou W. Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis. J. Neurol. 271(9), 5762–5777 (2024).
• An NMA of pharmacotherapies for chronic migraine (CM) which is subject to critical review in this article.
9.
Yang CP, Zeng BY, Chang CM et al. Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials. Neurotherapeutics 18(4), 2639–2650 (2021).
• An NMA of pharmacotherapies for CM which is subject to critical review in this article.
10.
Higgins J, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5 2024. (2024). http://www.cochrane.org/handbook
• Provides detailed guidelines on systematic review best practices.
11.
Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD's guidance for undertaking reviews in health care. (2009). https://www.york.ac.uk/media/crd/newpagesspring2025/Systematic_Reviews_CRD_guidance.pdf
• Provides detailed guidelines on systematic review best practices, including search strategy, screening strategy, and risk of bias assessment recommendations; a proposed list of items to consider in the critical appraisal of a systematic review is repurposed in this article as Table1.
12.
Centre for Reviews and Dissemination. Prospero: international prospective register of systematic reviews. (2026). https://www.crd.york.ac.uk/PROSPERO/
13.
Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 159(2), 130–137 (2013).
14.
Brignardello-Petersen R, Florez ID, Izcovich A et al. Grade approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 371, m3900 (2020).
15.
Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al. Cinema: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 17(4), e1003082 (2020).
16.
Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A randomized trial to evaluate onabotulinumtoxina for prevention of headaches in adolescents with chronic migraine. Headache 60(3), 564–575 (2020).
17.
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27(7), 814–823 (2007).
18.
Rothrock JF, Adams AM, Lipton RB et al. Forward study: evaluating the comparative effectiveness of onabotulinumtoxina and topiramate for headache prevention in adults with chronic migraine. Headache 59(10), 1700–1713 (2019).
19.
Aurora SK, Dodick DW, Turkel CC et al. Onabotulinumtoxina for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the preempt 1 trial. Cephalalgia 30(7), 793–803 (2010).
20.
Diener HC, Dodick DW, Aurora SK et al. Onabotulinumtoxina for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the preempt 2 trial. Cephalalgia 30(7), 804–814 (2010).
21.
Silberstein S, Diamond M, Hindiyeh NA et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the Phase III Promise-2 (prevention of migraine via intravenous ald403 safety and efficacy-2) study. J. Headache Pain 21(1), 120 (2020).
22.
Lipton RB, Goadsby PJ, Smith J et al. Efficacy and safety of eptinezumab in patients with chronic migraine: Promise-2. Neurology 94(13), e1365–e1377 (2020).
23.
Allergan. Botox (onabotulinumtoxina) [package insert]. (2023).
24.
Dodick DW, Lipton RB, Silberstein S et al. Eptinezumab for prevention of chronic migraine: a randomized Phase IIb clinical trial. Cephalalgia 39(9), 1075–1085 (2019).
25.
Silberstein SD, Dodick DW, Bigal ME et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 377(22), 2113–2122 (2017).
Information & Authors
Information
Published In
Copyright
© 2026 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 11 June 2026
Accepted: 3 September 2026
Published online: 22 September 2026
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Considerations for understanding systematic reviews and network meta-analyses in neurological applications: a review and critique in chronic migraine. (2026) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2026-0119
Export citation
Select the citation format you wish to export for this article or chapter.
